Ranjan Chrisanthar

The MDM2 Promoter SNP285C/309G Haplotype Diminishes Sp1 Transcription Factor Binding and Reduces Risk for Breast and Ovarian Cancer in Caucasians

Stian Knappskog, Merete Bjørnslett, Line M. Myklebust et al. · Cancer Cell · 2011 · 115 citations · Full text

Life Sciences, Genetics, Molecular Genetics +8

Predictive and Prognostic Impact of TP53 Mutations and MDM2 Promoter Genotype in Primary Breast Cancer Patients Treated with Epirubicin or Paclitaxel

Ranjan Chrisanthar, Stian Knappskog, Erik Løkkevik et al. · PLoS ONE · 2011 · 107 citations · Full text

Medicine, Oncology, Pharmacology +17

CHEK2 Mutations Affecting Kinase Activity Together With Mutations in TP53 Indicate a Functional Pathway Associated with Resistance to Epirubicin in Primary Breast Cancer

Ranjan Chrisanthar, Stian Knappskog, Erik Løkkevik et al. · PLoS ONE · 2008 · 96 citations · Full text

Medicine, Oncology, Pharmacology +16

Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer

Stian Knappskog, Ranjan Chrisanthar, Erik Løkkevik et al. · Breast Cancer Research · 2012 · 71 citations · Full text

Medicine, Cancer Biology, Oncology +17

White Blood Cell <i>BRCA1</i> Promoter Methylation Status and Ovarian Cancer Risk

Per Eystein Lønning, Elisabet O. Berge, Merete Bjørnslett et al. · Annals of Internal Medicine · 2018 · 53 citations

Medicine, Gynecology, Oncology +17